Thelansis

Glioblastoma (GBM) is the most aggressive diffuse glioma of astrocytic lineage and is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy.  GBM comprised of primary and secondary types, constituting distinct disease entities which evolve through different genetic pathways, affect patients at different ages, and likely differ in prognosis and response to therapy.  Primary de novo GBM accounts for more than 80% of GBM (6), occurs in older patients (mean age = 64 years), and typically shows epidermal growth factor receptor (EGFR) over expression, PTN (MMC I) mutation, CDKN2A (p16) deletion, and less frequently MDM2 amplification.    Epidemiology- Glioblastoma has an incidence of 2 to 3.4 per 100,000 population in US and Europe.   The competiti...